BDC Capital Growth Equity invests in Genacol Group

CPE News (9/1/2020) – The Genacol Group has raised undisclosed amount in equity investment from BDC Capital’s Growth Equity division to support its expansion plans.

Founded in 2000, the Genacol Group is a company specializing in natural supplements for joint health, whose products have proven effective in three independent clinical studies.

BDC Capital investment is part of the succession plan of Genacol Group’s founder, Guy Michaud, whose three sons also work at the company. Through the investment, BDC Capital became a minority shareholder among the Genacol Group’s shareholders alongside the Michaud family and the current president, Martin Vidal.

A BDC Capital representative will join Guy Michaud and Martin Vidal on Genacol board of directors.

photo credit: Genacol Group

News Release

Genacol welcomes BDC Capital as a shareholder for its expansion

Montreal, September 1, 2020—The Genacol Group, a company specializing in natural supplements for joint health, has received an equity investment from BDC Capital’s Growth Equity division to support its expansion plans. Founded in 2000, Genacol is today the leading natural joint supplement brand on the Quebec market. The company is also present elsewhere in Canada and in some 40 countries, where it is addressing growing markets. To achieve this, it relies on its strong relationships with major retailers and on online sales. The company continues to perform well in the current context and the pandemic has not altered its strategy and market development projects.

This long-term investment by BDC Capital is also part of the succession plan of Genacol Group’s founder, Guy Michaud, whose three sons also work at the company. Through its investment, BDC Capital takes a minority position among the Genacol Group’s shareholder base alongside the Michaud family and the current president, Martin Vidal. BDC Capital, which will sit on the Board of Directors and play an active role in the company, will notably help Genacol strengthen its governance in order to support the growth strategy and the intergenerational transition process.

“We are extremely proud to be able to count on the support of a quality financial partner such as BDC Capital to help us pursue our long-term growth plan both in Canada and on international markets,” said Mr. Vidal, President and CEO of Genacol. “BDC Capital has taken note of the significant growth we have posted in recent years and has agreed to invest in our growth strategy, which is very promising for the future of the Genacol brand in the long term.”

This transaction was led by Guillaume, Principal, Growth Equity, at BDC Capital’s Montreal office. “The Genacol Group has a strong brand with a great reputation and is known for its quality products, which puts it in an excellent position to pursue its growth outside Quebec,” said Mr. Felx. “The management team has defined a very clear growth strategy that is well anchored in the integrity and work ethic that drives the company. BDC Capital will be a committed partner in the company for several years to come.”

About the Genacol Group
Founded in 2000, the Genacol Group is a company specializing in natural supplements for joint health, whose products have proven effective in three independent clinical studies. Today, the company is the leading natural joint supplement brand on the Quebec market and has a presence elsewhere in Canada and in some 40 countries.

About BDC Capital
BDC Capital is the investment arm of BDC—Canada’s only bank devoted exclusively to entrepreneurs. With over $3 billion under management, BDC Capital serves as a strategic partner to the country’s most innovative firms. It offers a full range of capital and financing, from seed investments to transition capital. BDC Capital supports Canadian entrepreneurs with the ambition to stand out on the global stage. Visit bdc.ca/capital.

—30—